Cerus Return on Tangible Equity 2010-2025 | CERS
Current and historical return on tangible equity values for Cerus (CERS) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Cerus Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-06-30 | $-0.02B | $0.06B | -36.53% |
| 2025-03-31 | $-0.02B | $0.06B | -37.56% |
| 2024-12-31 | $-0.02B | $0.06B | -42.51% |
| 2024-09-30 | $-0.02B | $0.05B | -39.41% |
| 2024-06-30 | $-0.02B | $0.05B | -48.48% |
| 2024-03-31 | $-0.03B | $0.05B | -62.31% |
| 2023-12-31 | $-0.04B | $0.05B | -71.15% |
| 2023-09-30 | $-0.05B | $0.05B | -89.69% |
| 2023-06-30 | $-0.05B | $0.05B | -82.26% |
| 2023-03-31 | $-0.05B | $0.06B | -67.40% |
| 2022-12-31 | $-0.04B | $0.07B | -57.14% |
| 2022-09-30 | $-0.04B | $0.07B | -47.59% |
| 2022-06-30 | $-0.04B | $0.08B | -51.57% |
| 2022-03-31 | $-0.05B | $0.08B | -58.90% |
| 2021-12-31 | $-0.05B | $0.08B | -62.72% |
| 2021-09-30 | $-0.06B | $0.08B | -65.17% |
| 2021-06-30 | $-0.06B | $0.08B | -62.50% |
| 2021-03-31 | $-0.06B | $0.09B | -57.97% |
| 2020-12-31 | $-0.06B | $0.10B | -54.38% |
| 2020-09-30 | $-0.06B | $0.11B | -63.92% |
| 2020-06-30 | $-0.07B | $0.11B | -77.88% |
| 2020-03-31 | $-0.07B | $0.11B | -95.17% |
| 2019-12-31 | $-0.07B | $0.06B | -116.60% |
| 2019-09-30 | $-0.07B | $0.06B | -103.65% |
| 2019-06-30 | $-0.07B | $0.06B | -87.87% |
| 2019-03-31 | $-0.06B | $0.07B | -75.15% |
| 2018-12-31 | $-0.06B | $0.08B | -65.90% |
| 2018-09-30 | $-0.05B | $0.09B | -69.33% |
| 2018-06-30 | $-0.05B | $0.09B | -83.27% |
| 2018-03-31 | $-0.06B | $0.08B | -113.99% |
| 2017-12-31 | $-0.06B | $0.04B | -162.16% |
| 2017-09-30 | $-0.06B | $0.04B | -150.90% |
| 2017-06-30 | $-0.06B | $0.04B | -126.73% |
| 2017-03-31 | $-0.07B | $0.04B | -109.70% |
| 2016-12-31 | $-0.06B | $0.06B | -90.32% |
| 2016-09-30 | $-0.06B | $0.07B | -81.01% |
| 2016-06-30 | $-0.07B | $0.07B | -77.88% |
| 2016-03-31 | $-0.06B | $0.08B | -68.27% |
| 2015-12-31 | $-0.06B | $0.09B | -55.72% |
| 2015-09-30 | $-0.06B | $0.09B | -70.11% |
| 2015-06-30 | $-0.06B | $0.11B | -74.67% |
| 2015-03-31 | $-0.05B | $0.11B | -82.05% |
| 2014-12-31 | $-0.04B | $0.04B | -92.86% |
| 2014-09-30 | $-0.03B | $0.05B | -59.17% |
| 2014-06-30 | $-0.04B | $0.04B | -89.17% |
| 2014-03-31 | $-0.03B | $0.04B | -81.44% |
| 2013-12-31 | $-0.04B | $0.04B | -96.17% |
| 2013-09-30 | $-0.04B | $0.03B | -100.63% |
| 2013-06-30 | $-0.02B | $0.05B | -62.86% |
| 2013-03-31 | $-0.02B | $0.06B | -65.38% |
| 2012-12-31 | $-0.02B | $0.02B | -103.23% |
| 2012-09-30 | $-0.02B | $0.01B | -144.26% |
| 2012-06-30 | $-0.02B | $0.02B | -113.33% |
| 2012-03-31 | $-0.02B | $0.02B | -155.56% |
| 2011-12-31 | $-0.02B | $0.02B | -125.93% |
| 2011-09-30 | $-0.01B | $0.01B | -74.58% |
| 2011-06-30 | $-0.02B | $0.01B | -123.64% |
| 2011-03-31 | $-0.02B | $0.02B | -119.30% |
| 2010-12-31 | $-0.02B | $0.02B | -117.24% |
| 2010-09-30 | $-0.02B | $0.01B | -135.59% |
| 2010-06-30 | $-0.02B | $0.01B | -115.79% |
| 2010-03-31 | $-0.02B | $0.02B | -102.33% |
| 2009-12-31 | $-0.02B | $0.02B | -100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.251B | $0.180B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.644B | 26.81 |
| Boston Scientific (BSX) | United States | $156.695B | 37.37 |
| Stryker (SYK) | United States | $148.974B | 30.33 |
| EssilorLuxottica (ESLOY) | France | $142.491B | 0.00 |
| Medtronic (MDT) | Ireland | $117.956B | 16.63 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.926B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.457B | 24.85 |
| ResMed (RMD) | United States | $40.320B | 28.84 |
| Agilent Technologies (A) | United States | $35.497B | 22.93 |
| GE HealthCare Technologies (GEHC) | United States | $33.658B | 15.82 |
| Terumo (TRUMY) | Japan | $26.798B | 31.75 |
| Koninklijke Philips (PHG) | Netherlands | $26.557B | 17.57 |
| Insulet (PODD) | United States | $23.765B | 79.62 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.812B | 13.25 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.306B | 0.00 |
| Baxter (BAX) | United States | $12.532B | 9.68 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.947B | 29.19 |
| Lantheus Holdings (LNTH) | United States | $3.774B | 10.20 |
| Envista Holdings (NVST) | United States | $3.531B | 24.71 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.310B | 14.69 |
| Perrigo (PRGO) | Ireland | $3.269B | 8.16 |
| ICU Medical (ICUI) | United States | $3.136B | 21.35 |
| Haemonetics (HAE) | United States | $2.618B | 11.69 |
| Curaleaf Holdings (CURLF) | Canada | $2.259B | 0.00 |
| Acuren (TIC) | United States | $2.215B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.157B | 46.25 |
| QuidelOrtho (QDEL) | United States | $1.901B | 11.97 |
| Green Thumb Industries (GTBIF) | United States | $1.865B | 80.09 |
| AtriCure (ATRC) | United States | $1.850B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.618B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.559B | 18.40 |
| AdaptHealth (AHCO) | United States | $1.250B | 17.77 |
| Neogen (NEOG) | United States | $1.249B | 19.83 |
| BioLife Solutions (BLFS) | United States | $1.194B | 2492.00 |
| InMode (INMD) | Israel | $0.943B | 8.73 |
| Kestra Medical Technologies (KMTS) | United States | $0.909B | 0.00 |
| Valneva SE (VALN) | France | $0.752B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.727B | 0.00 |
| SNDL (SNDL) | Canada | $0.707B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.608B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.597B | 0.00 |
| ZimVie (ZIMV) | United States | $0.533B | 20.54 |
| Surmodics (SRDX) | United States | $0.491B | 0.00 |
| Evolus (EOLS) | United States | $0.486B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.476B | 16.39 |
| Canopy Growth (CGC) | Canada | $0.451B | 0.00 |
| CeriBell (CBLL) | United States | $0.439B | 0.00 |
| Owens & Minor (OMI) | United States | $0.383B | 3.40 |
| Sanuwave Health (SNWV) | United States | $0.364B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.343B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.317B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.300B | 0.00 |
| Brainsway (BWAY) | Israel | $0.290B | 59.00 |
| High Tide (HITI) | Canada | $0.290B | 0.00 |
| Omeros (OMER) | United States | $0.288B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.286B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.280B | 21.26 |
| TriSalus Life Sciences (TLSI) | United States | $0.255B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.241B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.238B | 0.00 |
| Organigram Global (OGI) | Canada | $0.232B | 0.00 |
| Exagen (XGN) | United States | $0.214B | 0.00 |
| Quanterix (QTRX) | United States | $0.211B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.199B | 16.59 |
| FitLife Brands (FTLF) | United States | $0.175B | 21.60 |
| Biote (BTMD) | United States | $0.172B | 5.69 |
| Jushi Holdings (JUSHF) | United States | $0.147B | 0.00 |
| Jin Medical (ZJYL) | China | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.114B | 0.00 |
| MacroGenics (MGNX) | United States | $0.107B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.70 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.090B | 0.00 |
| Apyx Medical (APYX) | United States | $0.076B | 0.00 |
| Agape ATP (ATPC) | $0.067B | 0.00 | |
| Rockwell Medical (RMTI) | United States | $0.062B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.059B | 0.00 |
| Safety Shot (SHOT) | United States | $0.058B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 32.21 |
| MariMed (MRMD) | United States | $0.054B | 0.00 |
| Zynex (ZYXI) | United States | $0.050B | 0.00 |
| Veru (VERU) | United States | $0.049B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 33.58 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.34 |
| Senestech (SNES) | United States | $0.024B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| Sharps Technology (STSS) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |